Search Results for: "Clinic Roundup"
-
Clinic Roundup
The primary endpoint of the trial is clinical response rateBioWorld Today | Friday, May 11, 2012 -
Clinic Roundup
The primary endpoint is overall response rate, lasting at least four monthsBioWorld Today | Tuesday, May 8, 2012 -
Clinic Roundup
The primary endpoint is an estimation of progression-free survival, while secondary endpoints include objective response rate and clinical benefit rate of imetelstat when added to paclitaxelBioWorld Today | Friday, May 4, 2012 -
Clinic Roundup
Preliminary results in the intent-to-treat (ITT) population showed a trend favoring the ficlatuzumab/gefitinib combination in the primary endpoint of overall response rate (ORR), though results did not reach statistical significanceBioWorld Today | Thursday, May 3, 2012 -
Clinic Roundup
The trial will compare carfilzomib/lenolidomide/dexamethasone against lenolidomide and dexamethasone in 780 patients with relapsed multiple myeloma at about 200 sites, with a primary endpoint of progression-free survival and secondary endpoints including overall survival, overall response rate, duration of response, disease control rate, safety, time-to-progression and time-to-next-treatmentBioWorld Today | Friday, February 24, 2012 -
Clinic Roundup
Overall response rate (ORR) – the trial's primary endpoint – in the MTD group was 20 percent in patients treated with tesetaxel as second-line therapyBioWorld Today | Friday, January 20, 2012 -
Clinic Roundup
About 95 patients in a first or second relapse following standard therapy will be enrolled, and endpoints will include the progression rate at six months, objective response rate, overall survival and progression-free survivalBioWorld Today | Thursday, January 5, 2012 -
Clinic Roundup
Emergent BioSolutions Inc., of Rockville, Md., said it started a Phase II study of TRU-016 in combination with bendamustine in patients with relapsed chronic lymphocytic leukemia, triggering a $6 million milestone payment to Emergent by Abbott, of Abbot Park, Ill. The study is designed to compare the combination of the anti-DC37 monospecific protein therapeutic plus bendamustine to bendamustine alone in about 100 randomized patients, with a primary endpoint of overall response rate defined byBioWorld Today | Thursday, December 29, 2011 -
Clinic Roundup
Endpoints include response rate and progression-free survivalBioWorld Today | Thursday, December 22, 2011 -
Clinic Roundup
The primary endpoint is response rate, as measured by the SLE Responder IndexBioWorld Today | Friday, December 16, 2011 -
Clinic Roundup
and one outside – and will enroll previously untreated follicular lymphoma patients, with the primary objectives of complete response rate and progression-free survival...Secondary objectives will include event-free survival, overall survival, overall response rate, health-related quality of life and safetyBioWorld Today | Thursday, December 15, 2011 -
Clinic Roundup
The primary efficacy endpoint for the trial is intra-cranial response rate...secondary endpoints include progression-free survival and objective tumor response ratesBioWorld Today | Tuesday, December 13, 2011 -
Clinic Roundup
Ltd.'s Uloric (febuxostat) increased response rate (gout patients achieving serum uric acid levels of 5 and 4 mg/dL) by 73 percent (p = 0.013BioWorld Today | Friday, December 9, 2011 -
Clinic Roundup
Clinical response rates of 93 percent, 96 percent and 88 percent for the 100 U/kg, 50 U/kg and 2100 U Rhucin doses, respectively, were observed compared with 41 percent in the placebo groupBioWorld Today | Thursday, December 8, 2011 -
Clinic Roundup
The study also showed trends in favor of TTF compared to chemotherapy in PFS6 (21.4 percent vs. 15.2 percent, respectively, p = ns) and radiological response rates (14 percent vs. 9.6 percent, respectively, p = nsBioWorld Today | Tuesday, November 22, 2011 -
Clinic Roundup
The study's primary objective is to determine the antitumor effects of Imprime PGG, an immunomodulatory drug, when used in combination with a monoclonal antibody and standard chemotherapy, based on overall response rate as assessed by RECIST criteriaBioWorld Today | Friday, November 18, 2011 -
Clinic Roundup
Ltd., of Seoul, South Korea, said interim data from its Phase II trial in Stage III non-small-cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy demonstrated an 80 percent immune response rateBioWorld Today | Wednesday, November 16, 2011 -
Clinic Roundup
At the best dose, the response rate was 75 percent, with 38 percent remitting five weeks after treatmentBioWorld Today | Wednesday, October 26, 2011 -
Clinic Roundup
In a previous Phase Ib trial, once-daily oral IPI-926 and gemcitabine generated a response rate of 31 percent, compared to a historic overall response rate of less than 10 percent for gemcitabineBioWorld Today | Tuesday, October 18, 2011 -
Clinic Roundup
The primary objective is to determine the hematologic improvement-erythroid response rate, as determined by clinically significant transfusion reduction or independenceBioWorld Today | Friday, October 14, 2011
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.